Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.58 |
| ▸ | CYP26A1 | O43174 | 6/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13982628 | 0.89 | CYP3A4 (0.60) | MAOBCYP26A1CYP3A4MAPTHPGD | |
| SCHEMBL29827413 | 0.89 | CYP3A4 (0.60) | MAOBCYP26A1CYP3A4MAPTHPGD | |
| SCHEMBL8461403 | 0.82 | MAOB (0.52) | MAOBCYP26A1CYP3A4MAPTHPGD | |
| SCHEMBL23882822 | 0.82 | MAOB (0.51) | MAOBCYP26A1CYP3A4MAPTHPGD | |
| SCHEMBL31500685 | 0.82 | MAOB (0.55) | MAOBCYP26A1CYP3A4MAPTHPGD | |
| SCHEMBL31500686 | 0.82 | MAOB (0.55) | MAOBCYP26A1CYP3A4MAPTHPGD | |
| SCHEMBL8461434 | 0.82 | MAOB (0.70) | MAOBCYP26A1CYP3A4MAPTHPGD | |
| SCHEMBL8466024 | 0.81 | MAOB (0.54) | MAOBCYP26A1CYP3A4MAPTHPGD | |
| SCHEMBL8462840 | 0.80 | CYP19A1 (0.60) | MAOBCYP26A1CYP3A4MAPTHPGD | |
| SCHEMBL8465454 | 0.79 | MAOB (0.56) | MAOBCYP26A1CYP3A4MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431166-B2 | Composition comprising the extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2013-04-30 | — | — | US | disclosed |
| US-8431166-B2 | Composition comprising the extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2013-04-30 | — | — | US | disclosed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | disclosed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | disclosed |
| WO-2010120029-A1 | COMPOSITION COMPRISING THE EXTRACT OF ANEMARRHENA ASPHODELOIDES BUNGE OR THE COMPOUNDS ISOLATED FROM THE SAME FOR PREVENTING AND TREATING LIPID METABOLISM DISORDER | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | FABP4, ACACB, LIPC | MAOB 3070/4885CYP26A1 927/4885CYP3A4 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.